100 related articles for article (PubMed ID: 27188740)
21. Clinically Important Benefits and Harms of Monoclonal Antibodies Targeting Amyloid for the Treatment of Alzheimer Disease: A Systematic Review and Meta-Analysis.
Ebell MH; Barry HC; Baduni K; Grasso G
Ann Fam Med; 2024; 22(1):50-62. PubMed ID: 38253509
[TBL] [Abstract][Full Text] [Related]
22. Pharmacological Agents Targeting γ-Secretase Increase Risk of Cancer and Cognitive Decline in Alzheimer's Disease Patients: A Systematic Review and Meta-Analysis.
Penninkilampi R; Brothers HM; Eslick GD
J Alzheimers Dis; 2016 Jul; 53(4):1395-404. PubMed ID: 27392862
[TBL] [Abstract][Full Text] [Related]
23. Role of statins in Alzheimer's disease: a retrospective meta-analysis for commonly investigated clinical parameters in RCTs.
Pandey RD; Gupta PP; Jha D; Kumar S
Int J Neurosci; 2013 Aug; 123(8):521-5. PubMed ID: 23438287
[TBL] [Abstract][Full Text] [Related]
24. Suitability of the Clinical Dementia Rating-Sum of Boxes as a single primary endpoint for Alzheimer's disease trials.
Coley N; Andrieu S; Jaros M; Weiner M; Cedarbaum J; Vellas B
Alzheimers Dement; 2011 Nov; 7(6):602-610.e2. PubMed ID: 21745761
[TBL] [Abstract][Full Text] [Related]
25. Effects of memantine on cognition in patients with moderate to severe Alzheimer's disease: post-hoc analyses of ADAS-cog and SIB total and single-item scores from six randomized, double-blind, placebo-controlled studies.
Mecocci P; Bladström A; Stender K
Int J Geriatr Psychiatry; 2009 May; 24(5):532-8. PubMed ID: 19274640
[TBL] [Abstract][Full Text] [Related]
26. A randomized, double-blind, placebo-controlled study of the efficacy and safety of donepezil in patients with Alzheimer's disease in the nursing home setting.
Tariot PN; Cummings JL; Katz IR; Mintzer J; Perdomo CA; Schwam EM; Whalen E
J Am Geriatr Soc; 2001 Dec; 49(12):1590-9. PubMed ID: 11843990
[TBL] [Abstract][Full Text] [Related]
27. The peroxisome proliferators activated receptor-gamma agonists as therapeutics for the treatment of Alzheimer's disease and mild-to-moderate Alzheimer's disease: a meta-analysis.
Cheng H; Shang Y; Jiang L; Shi TL; Wang L
Int J Neurosci; 2016; 126(4):299-307. PubMed ID: 26001206
[TBL] [Abstract][Full Text] [Related]
28. Growth hormone secretagogue MK-677: no clinical effect on AD progression in a randomized trial.
Sevigny JJ; Ryan JM; van Dyck CH; Peng Y; Lines CR; Nessly ML;
Neurology; 2008 Nov; 71(21):1702-8. PubMed ID: 19015485
[TBL] [Abstract][Full Text] [Related]
29. Psychometric evaluation of ADAS-Cog and NTB for measuring drug response.
Karin A; Hannesdottir K; Jaeger J; Annas P; Segerdahl M; Karlsson P; Sjögren N; von Rosen T; Miller F
Acta Neurol Scand; 2014 Feb; 129(2):114-22. PubMed ID: 23763450
[TBL] [Abstract][Full Text] [Related]
30. Efficacy of antibody-based therapies to treat Alzheimer's disease: just a matter of timing?
Cedernaes J; Schiöth HB; Benedict C
Exp Gerontol; 2014 Sep; 57():104-6. PubMed ID: 24835192
[TBL] [Abstract][Full Text] [Related]
31. Safety and efficacy of active and passive immunotherapy in mild-to-moderate Alzheimer's disease: A systematic review and network meta-analysis.
Foroutan N; Hopkins RB; Tarride JE; Florez ID; Levine M
Clin Invest Med; 2019 Mar; 42(1):E53-E65. PubMed ID: 30904037
[TBL] [Abstract][Full Text] [Related]
32. Disease progression meta-analysis model in Alzheimer's disease.
Ito K; Ahadieh S; Corrigan B; French J; Fullerton T; Tensfeldt T;
Alzheimers Dement; 2010 Jan; 6(1):39-53. PubMed ID: 19592311
[TBL] [Abstract][Full Text] [Related]
33. Detecting treatment effects with combinations of the ADAS-cog items in patients with mild and moderate Alzheimer's disease.
Ihl R; Ferris S; Robert P; Winblad B; Gauthier S; Tennigkeit F
Int J Geriatr Psychiatry; 2012 Jan; 27(1):15-21. PubMed ID: 21384431
[TBL] [Abstract][Full Text] [Related]
34. Long-term effects of Abeta42 immunisation in Alzheimer's disease: follow-up of a randomised, placebo-controlled phase I trial.
Holmes C; Boche D; Wilkinson D; Yadegarfar G; Hopkins V; Bayer A; Jones RW; Bullock R; Love S; Neal JW; Zotova E; Nicoll JA
Lancet; 2008 Jul; 372(9634):216-23. PubMed ID: 18640458
[TBL] [Abstract][Full Text] [Related]
35. Assessment of CSF Aβ42 as an aid to discriminating Alzheimer's disease from other dementias and mild cognitive impairment: a meta-analysis of 50 studies.
Tang W; Huang Q; Wang Y; Wang ZY; Yao YY
J Neurol Sci; 2014 Oct; 345(1-2):26-36. PubMed ID: 25086857
[TBL] [Abstract][Full Text] [Related]
36. Gantenerumab for early Alzheimer's disease: a systematic review and meta-analysis.
Menegaz de Almeida A; Leite M; Lopes LM; Gomes Lima P; Siegloch Barros ML; Rocha Pinheiro S; Andrade Í; Viana P; Morbach V; Marinheiro G; de Oliveira R; Pinheiro AC
Expert Rev Neurother; 2024 Jun; ():1-8. PubMed ID: 38879828
[TBL] [Abstract][Full Text] [Related]
37. Two-year follow-up of amyloid deposition in patients with Alzheimer's disease.
Engler H; Forsberg A; Almkvist O; Blomquist G; Larsson E; Savitcheva I; Wall A; Ringheim A; Långström B; Nordberg A
Brain; 2006 Nov; 129(Pt 11):2856-66. PubMed ID: 16854944
[TBL] [Abstract][Full Text] [Related]
38. Clinical trials in Alzheimer's disease. Calculating Alzheimer's Disease Assessment Scale-cognitive subsection with the data from the consortium to establish a registry for Alzheimer's disease.
Gillen TE; Gregg KM; Yuan H; Kurth MC; Krishnan KR
Psychopharmacol Bull; 2001; 35(2):83-96. PubMed ID: 12397889
[TBL] [Abstract][Full Text] [Related]
39. Analysis of outcome in retrieved dropout patients in a rivastigmine vs placebo, 26-week, Alzheimer disease trial.
Farlow M; Potkin S; Koumaras B; Veach J; Mirski D
Arch Neurol; 2003 Jun; 60(6):843-8. PubMed ID: 12810489
[TBL] [Abstract][Full Text] [Related]
40. Rivastigmine transdermal patch and capsule in Alzheimer's disease: influence of disease stage on response to therapy.
Farlow MR; Grossberg GT; Meng X; Olin J; Somogyi M
Int J Geriatr Psychiatry; 2011 Dec; 26(12):1236-43. PubMed ID: 22068922
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
